Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 88.32% from the stock's current price.
Oculis Stock Performance
Oculis stock traded down $0.35 during midday trading on Monday, hitting $15.93. The company's stock had a trading volume of 40,801 shares, compared to its average volume of 36,550. Oculis has a 1-year low of $9.60 and a 1-year high of $18.00. The company has a 50-day moving average price of $14.01 and a two-hundred day moving average price of $12.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27.
Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.13). The business had revenue of $0.27 million during the quarter, compared to analysts' expectations of $0.28 million. Oculis had a negative return on equity of 71.90% and a negative net margin of 8,043.28%. As a group, research analysts anticipate that Oculis will post -2.19 earnings per share for the current year.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Featured Stories
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
